The BE (2)-M17 cell line has a better dopaminergic phenotype than the traditionally used for Parkinson's research SH-SY5Y, which is mostly serotonergic

被引：8

作者：

Carvajal-Oliveros, Angel ^{[1
]}

Uriostegui-Arcos, Maritere ^{[1
,2
]}

Zurita, Mario ^{[1
]}

Melchy-Perez, Erika I. ^{[1
]}

Narvaez-Padilla, Veronica ^{[3
]}

Reynaud, Enrique ^{[1
]}

机构：

[1] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62210, Morelos, Mexico

[2] Boston Univ, Dept Biol, Boston, MA USA

[3] Univ Autonoma Estado Morelos, Ctr Invest Dinam Celular, Cuernavaca, Mexico

来源：

IBRO NEUROSCIENCE REPORTS | 2022年 / 13卷

关键词：

SH-SY5Y cell line; Parkinson's disease; Dopaminergic neurons; Serotonergic neurons; Staurosporine; Retinoic acid; IN-VITRO MODEL; ALPHA-SYNUCLEIN; DISEASE;

D O I：

10.1016/j.ibneur.2022.11.007

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

SH-SY5Y is a cell line derived from human neuroblastoma. It is one of the most widely used in vitro models to study Parkinson's disease. Surprisingly, it has been found that it does not develop a dopaminergic phenotype after differentiation, questioning its usefulness as a Parkinson's model. There are other in vitro models with better dopaminergic characteristics. BE (2)-M17 is a human neuroblastoma cell line that differentiates when treated with retinoic acid. We compared the dopaminergic and serotonergic properties of both cell lines. BE (2)-M17 has higher basal levels of dopaminergic markers and acquires a serotonergic phenotype during differentiation while maintaining the dopaminergic phenotype. SH-SY5Y has higher basal levels of serotonergic markers but does not acquire a dopaminergic phenotype upon differentiation.

引用

页码：543 / 551

页数：9

共 33 条

[1] Biochemical characterization of proliferative and differentiated SH-SY5Y cell line as a model for Parkinson's disease [J].

Alrashidi, Haya ;

Eaton, Simon ;

Heales, Simon .

NEUROCHEMISTRY INTERNATIONAL, 2021, 145

[2] Morphological and functional differentiation in BE (2)-M17 human neuroblastoma cells by treatment with Trans-retinoic acid [J].

Andres, Devon ;

Keyser, Brian M. ;

Petrali, John ;

Benton, Betty ;

Hubbard, Kyle S. ;

McNutt, Patrick M. ;

Ray, Radharaman .

BMC NEUROSCIENCE, 2013, 14

[3]

Baba M, 1998, AM J PATHOL, V152, P879

[4] α-Synuclein overexpression increases dopamine toxicity in BE(2)-M17 cells [J].

Bisaglia, Marco ;

Greggio, Elisa ;

Maric, Dragan ;

Miller, David W. ;

Cookson, Mark R. ;

Bubacco, Luigi .

BMC NEUROSCIENCE, 2010, 11

[5] Studying the Contribution of Serotonin to Neurodevelopmental Disorders. Can This Fly? [J].

Carvajal-Oliveros, Angel ;

Campusano, Jorge M. .

FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2021, 14

[6] Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research [J].

Cheung, Yuen-Ting ;

Lau, Way Kwok-Wai ;

Yu, Man-Shan ;

Lai, Cora Sau-Wan ;

Yeung, Sze-Chun ;

So, Kwok-Fai ;

Chang, Raymond Chuen-Chung .

NEUROTOXICOLOGY, 2009, 30 (01) :127-135

[7] Stem cells: Promises versus limitations [J].

Choumerianou, Despoina M. ;

Dimitriou, Helen ;

Kalmanti, Maria .

TISSUE ENGINEERING PART B-REVIEWS, 2008, 14 (01) :53-60

[8] Epidemiology of Parkinson's disease [J].

de Lau, Lonneke M. L. ;

Breteler, Monique M. B. .

LANCET NEUROLOGY, 2006, 5 (06) :525-535

[9] Parkinson disease: from pathology to molecular disease mechanisms [J].

Dexter, David T. ;

Jenner, Peter .

FREE RADICAL BIOLOGY AND MEDICINE, 2013, 62 :132-144

[10]

Falkenburger BH, 2006, J NEURAL TRANSM-SUPP, P261

← 1 2 3 4 →